Dhansa Labs Q2 FY27 Revenue Reaches ₹38.6 Crore, Profit ₹1.7 Crore
Key highlights
- Dhansa Labs reported Q2 FY27 consolidated sales of ₹38.6 crore, up 26.2% sequentially from ₹30.6 crore.
- Q2 FY27 net profit was ₹1.7 crore, compared with ₹0.7 crore in Q1 FY27.
- Operating profit margin improved by 3 basis points to 8.7% in Q2 FY27.
- Dhansa Labs fully utilised ₹21.62 crore received from a ₹50.00 crore convertible-warrant issue.
powered by IRIS

Dhansa Labs Limited reported consolidated revenue of ₹38.6 crore and net profit of ₹1.7 crore for Q2 FY27 ended September 30, 2026, with operating margin at 8.7%. The filing also disclosed utilisation of ₹21.62 crore received from convertible warrants, making the quarterly update relevant for investors tracking earnings and capital deployment.
Know Dhansa Labs inside out
Results, valuation, peers and who's buying, in one view.
What did Dhansa Labs report for Q2 FY27?
Dhansa Labs reported consolidated sales of ₹38.6 crore for the quarter ended September 30, 2026, compared with ₹30.6 crore in the preceding June 2026 quarter. Operating profit stood at ₹3.3 crore, while net profit was ₹1.7 crore and earnings per share were ₹0.64.
The company’s operating profit margin was 8.7%, compared with 8.6% in the June 2026 quarter. Net profit margin was 4.4%, up from 2.4% in the prior quarter. The reported quarterly figures show sequential sales growth of 26.2%, operating-profit growth of 26.5%, and net-profit growth of 132.3%.
A separate revenue disclosure states that revenue from operations was ₹40.01 crore in Q2 2026, compared with ₹39.89 crore in Q2 2025. The available information does not specify whether this year-on-year comparison refers to standalone or consolidated accounts, while the detailed quarterly table identifies its figures as consolidated. Investors should therefore distinguish between the two disclosed revenue presentations.
How did the board meeting and results filing unfold?
Dhansa Labs’ board met on November 14, 2026, to consider and approve financial results and other business matters. The company had informed the exchange about the meeting on November 5, 2026, and submitted the financial results for the period ended September 30, 2026 on November 14.
The board approved unaudited standalone and consolidated financial results for the second quarter and first half of FY27. The results were filed at 10:51 pm on November 14, according to the corporate announcement details provided. The company had previously followed a similar timing pattern, filing Q1 FY27 results on August 14, 2026, 45 days after the quarter end.
The November 14 meeting also approved the appointment of M/s. K.K. Baranwal & Associates as internal auditor with effect from that date. The disclosed agenda did not mention a dividend, bonus issue, stock split, or buyback proposal for Dhansa Labs.
Got a follow-up? Ask IRIS
What was disclosed about Dhansa Labs’ convertible warrants?
Dhansa Labs disclosed that it had allotted 1,08,69,565 convertible warrants at ₹46 each during the prior period. The total size of the warrant issue was ₹50.00 crore, based on the disclosed amount of ₹4,999.99 lakh.
As of September 30, 2026, the company had received ₹21.62 crore from the warrant issue. It said the entire received amount had been utilised for capital expenditure, advances for plant and machinery, and general corporate purposes. The filing does not provide a further category-wise break-up of this utilisation.
This disclosure is material because proceeds from warrants can affect a company’s funding position and, upon conversion, its equity-share base. The filing establishes the funds received and their stated use, but it does not provide a timeline for future conversions or additional capital expenditure.
Why do the quarterly numbers matter to investors?
The Q2 figures show that Dhansa Labs recorded higher sales, operating profit, and net profit than in Q1 FY27. The operating margin improvement was limited to 3 basis points, but the net margin increased by 200 basis points to 4.4%, alongside the rise in quarterly profit to ₹1.7 crore.
The year-on-year revenue information indicates a smaller increase, with revenue from operations rising to ₹40.01 crore from ₹39.89 crore. Since the supplied data contains both standalone and consolidated references without a complete reconciliation, readers should use the company’s detailed financial statements to assess comparable periods and accounting scope.
The company operates in the fertilizers and agrochemicals segment. For investors, the reported result provides a current view of quarterly operating performance, while the warrant-proceeds disclosure adds information about how the company has funded capital expenditure and plant-and-machinery advances.
What is the wider corporate and shareholder context?
Dhansa Labs held its 41st annual general meeting on September 26, 2026. Shareholders considered the financial statements for the year ended March 31, 2026, ratified the cost auditor’s remuneration, and approved the resolutions placed before them.
All four ordinary resolutions received 100% votes in favour among votes polled, according to the voting-results disclosure. A total of 1,77,69,420 votes were polled out of 2,69,03,340 shares, representing 66% of outstanding shares. The disclosed resolutions included adoption of standalone and consolidated audited financial statements and reappointment of director Arpit Gupta, who was liable to retire by rotation.
The AGM voting outcome and the November board decisions provide governance context alongside the quarterly financial results. Neither announcement provides a share-price movement, valuation metric, or management outlook, so no such market assessment can be drawn from the available disclosures.
Conclusion
Dhansa Labs’ Q2 FY27 filing reported consolidated sales of ₹38.6 crore, operating profit of ₹3.3 crore, and net profit of ₹1.7 crore, with operating margin at 8.7%. The company also confirmed that it had fully used ₹21.62 crore received from its ₹50.00 crore convertible-warrant issue for stated operational and corporate purposes.
Investors can watch for subsequent financial disclosures that clarify performance across standalone and consolidated accounts, as well as any future updates on the remaining warrant issue, conversions, capital expenditure, or plant-and-machinery advances. The company’s next scheduled results announcement was not disclosed in the supplied information.


